Sector
PharmaceuticalsOpen
₹611Prev. Close
₹613.4Turnover(Lac.)
₹8,079.11Day's High
₹617.8Day's Low
₹594.9552 Week's High
₹646.252 Week's Low
₹385.45Book Value
₹80.4Face Value
₹2Mkt Cap (₹ Cr.)
32,295.83P/E
132.57EPS
4.63Divi. Yield
0.13The said transaction falls under related party transactions. However, the same is being carried at arm’s length price.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 107.79 | 107.73 | 107.47 | 107.32 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,099.26 | 3,949.09 | 3,280.74 | 2,604.92 |
Net Worth | 4,207.05 | 4,056.82 | 3,388.21 | 2,712.24 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 4,707.04 | 4,768.72 | 2,797.33 | 2,026.84 |
yoy growth (%) | -1.29 | 70.47 | 38.01 | 7.13 |
Raw materials | -2,208.56 | -2,175.13 | -1,402.54 | -1,056.4 |
As % of sales | 46.92 | 45.61 | 50.13 | 52.12 |
Employee costs | -445.14 | -401.88 | -323.99 | -238.14 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 975.41 | 1,274.63 | 304.48 | 240.9 |
Depreciation | -235.48 | -196.64 | -183.85 | -121.23 |
Tax paid | -225.32 | -318.52 | -37.43 | -67.76 |
Working capital | 145.83 | 684.91 | 246.73 | 42.81 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -1.29 | 70.47 | 38.01 | 7.13 |
Op profit growth | -14.88 | 164.78 | 39.5 | -1.22 |
EBIT growth | -20.08 | 241.8 | 23.97 | -7.49 |
Net profit growth | -21.54 | 258.03 | 54.23 | -13.41 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 5,040.83 | 6,040.55 | 4,935.57 | 4,813.51 | 2,831.72 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,040.83 | 6,040.55 | 4,935.57 | 4,813.51 | 2,831.72 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 26.34 | 6 | 15.3 | 23.66 | 5.92 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director & CEO
CHAVA SATYANARAYANA
Executive Director & CFO
VENKATA RAVI KUMAR VANTARAM
Independent Director
Aruna Bhinge
Independent Director
Rajesh Koshy Chandy
Chairman & Independent Directo
Ravindranath Kancherla
Executive Director
Venkata Lakshmana Rao Chunduru
Independent Director
Karnam Sekar
Executive Director
KRISHNA CHAITANYA CHAVA
Vice President & CS
G Venkateswar Reddy
Executive Director
Soumya Chava
Independent Director
Ramesh Subrahmanian
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Laurus Labs Ltd
Summary
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh. Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The companys strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing donor-funded access-to-medicines markets of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses. Further, it is increasingly focused towards growing its integrated generics finished dosage forms (FDFs) business in which it has made significant investments.Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture
Read More
The Laurus Labs Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹598.9 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Laurus Labs Ltd is ₹32295.83 Cr. as of 01 Apr ‘25
The PE and PB ratios of Laurus Labs Ltd is 132.57 and 7.75 as of 01 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Laurus Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Laurus Labs Ltd is ₹385.45 and ₹646.2 as of 01 Apr ‘25
Laurus Labs Ltd's CAGR for 5 Years at 57.18%, 3 Years at 1.26%, 1 Year at 56.34%, 6 Month at 32.31%, 3 Month at 4.43% and 1 Month at 16.35%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.